This one-day conference will be held on Thursday 22nd October 2015 at the National Heart and Lung Institute, Imperial College, London and is organised by the APS Microbiology and Anti-infectives Focus Group.
Meeting Format:
We are delighted to announce an exciting programme of high profile speakers who are leading experts and opinion formers in the fields of antimicrobial resistance, antibiotic discovery, novel therapeutic target development and representatives of academia, the pharmaceutical industry, SMEs and the major UK funding bodies.
Key Opinion Leader Contributions from Internationally-Renowned Speakers Including:
The keynote lecture will be delivered by Professor Sir Anthony Coates, Professor of Medical Microbiology at St George's, University of London and Chief Scientist officer at Helperby, a spin-out of the UK’s University of London St George’s. Anthony Coates is one of the world’s foremost experts in antibiotic resistance.
In addition, there will be sessions on novel therapeutic targets for anti-infective development, antibiotic discovery from natural sources, novel antibiotic discovery platforms, the SME perspective and ‘meet the funders’.
Meeting Format:
We are delighted to announce an exciting programme of high profile speakers who are leading experts and opinion formers in the fields of antimicrobial resistance, antibiotic discovery, novel therapeutic target development and representatives of academia, the pharmaceutical industry, SMEs and the major UK funding bodies.
Key Opinion Leader Contributions from Internationally-Renowned Speakers Including:
The keynote lecture will be delivered by Professor Sir Anthony Coates, Professor of Medical Microbiology at St George's, University of London and Chief Scientist officer at Helperby, a spin-out of the UK’s University of London St George’s. Anthony Coates is one of the world’s foremost experts in antibiotic resistance.
In addition, there will be sessions on novel therapeutic targets for anti-infective development, antibiotic discovery from natural sources, novel antibiotic discovery platforms, the SME perspective and ‘meet the funders’.
